Cataract News and Research

Latest Cataract News and Research

Omeros seeks EMA's approval to market OMS302 for patients undergoing ILR surgery

Omeros Corporation today announced that it recently submitted a Marketing Authorization Application to the European Medicines Agency seeking approval to market OMS302 for use in patients undergoing intraocular lens replacement surgery in the European Union.

10 Sep 2013

Study: People with cataract-related vision loss who undergo cataract surgery live longer

People with cataract-related vision loss who have had cataract surgery to improve their sight are living longer than those with visual impairment who chose not to have the procedure, according to an Australian cohort study published this month in Ophthalmology, the journal of the American Academy of Ophthalmology. After comparing the two groups, the researchers found a 40 percent lower long-term mortality risk in those who had the surgery.

5 Sep 2013

Meta-analysis indicates protective effect of statins in preventing cataracts

Cataracts are the leading cause of visual impairment worldwide affecting more than 20 million people. Statins are among the most commonly prescribed medications. In the USA they are prescribed to 1 in 3 people over 45 years of age at a cost of $35 billion annually.

2 Sep 2013

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO).

29 Aug 2013

Study reveals elegant circuit in visual system helps dictate how eyes connect to brain

A study in mice reveals an elegant circuit within the developing visual system that helps dictate how the eyes connect to the brain. The research, funded by the National Institutes of Health, has implications for treating amblyopia, a vision disorder that occurs when the brain ignores one eye in favor of the other.

26 Aug 2013

STAAR Surgical receives regulatory approval for its Visian ICL with CentraFLOW technology in India

STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, today announced that it has received regulatory approval to market its Visian Implantable Collamer Lens (ICL) with CentraFLOW technology from the CDSCO in India.

19 Aug 2013

Oraya Therapy Stereotactic Radiotherapy for treatment of wet AMDs now available at Optegra

Oraya Therapeutics, Inc. announced today that the Oraya Therapy Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD) is now available at Optegra Manchester Eye Hospital, becoming the second facility in the UK to provide the therapy.

14 Aug 2013

Omeros announces financial results for second quarter of 2013

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the second quarter of 2013.

12 Aug 2013

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity from baseline compared to laser photocoagulation at 52 weeks.

6 Aug 2013

NIH-funded study of aquaporin proteins could hold clues to cataract

Researchers have achieved dynamic, atomic-scale views of a protein needed to maintain the transparency of the lens in the human eye. The work, funded in part by the National Institutes of Health, could lead to new insights and drugs for treating cataract and a variety of other health conditions.

6 Aug 2013

Study opens door to possible treatments for variety of mitochondrial diseases

By borrowing a tool from bacteria that infect plants, scientists have developed a new approach to eliminate mutated DNA inside mitochondria-the energy factories within cells. Doctors might someday use the approach to treat a variety of mitochondrial diseases, including the degenerative eye disease Leber hereditary optic neuropathy. The research, published online today in Nature Medicine, was funded by the National Eye Institute, a part of the National Institutes of Health.

5 Aug 2013

Researchers find a crucial on-off switch in visual development

A discovery by a University of Maryland-led research team offers hope for treating "lazy eye" and other serious visual problems that are usually permanent unless they are corrected in early childhood.

2 Aug 2013

Omeros submits OMS302 NDA to FDA for patients undergoing ILR surgery

Omeros Corporation announced that the company recently submitted a New Drug Application to the U.S. Food and Drug Administration for approval of OMS302 for use in patients undergoing intraocular lens replacement surgery.

1 Aug 2013

Patient-reported outcomes may lead to new insights for improving cataract care

Cataract surgery can lead to good results from a clinical standpoint yet have poor outcomes from the patient's point of view, reports a study, "Analyzing Patient-Reported Outcomes to Improve Cataract Care", appearing in the August issue of Optometry and Vision Science, official journal of the American Academy of Optometry.

30 Jul 2013

Tel Aviv researcher says lessons from Israel's health-care system could optimize eye health

According to the World Health Organization, 80% of blindness is preventable or treatable - but it remains a severe health concern across the globe, even in industrialized countries.

11 Jul 2013

Eleven Biotherapeutics reports positive results from EBI-005 Phase 1b/2a study in patients with DED

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today positive topline clinical results from a 6-week randomized, double-masked, placebo-controlled Phase 1b/2a study of EBI-005 in patients with dry eye disease.

28 Jun 2013

Advanced optical measures may help predict change in visual acuity, study says

Sophisticated new optical quality metrics can identify older adults likely to have more rapid age-related declines in vision, suggests a study, "Factors Accounting for the 4-Year Change in Acuity in Patients Between 50 and 80 Years", in the July issue of Optometry and Vision Science, official journal of the American Academy of Optometry.

25 Jun 2013

STAAR Surgical to market Visian ICL with CentraFLOW technology in Korea, Argentina

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that it has received regulatory approvals to market its Visian Implantable Collamer Lens with CentraFLOW technology from the KFDA in Korea and the ANMAT in Argentina.

17 Jun 2013

pSivida reports that NICE issues draft guidance for use of ILUVIEN for pseudophakic patients with DME

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the United Kingdom's National Institute for Health and Care Excellence issued draft guidance recommending ILUVIEN for the treatment of pseudophakic patients (those who have undergone prior cataract surgery) with chronic diabetic macular edema considered insufficiently responsive to available therapies.

15 Jun 2013

NICE Appraisal Committee reconfirms clinical effectiveness of ILUVIEN

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Appraisal Committee of the United Kingdom's National Institute for Health and Care Excellence has issued a positive Appraisal Consultation Document on ILUVIEN for the treatment of pseudophakic patients with chronic diabetic macular edema considered insufficiently responsive to available therapies.

14 Jun 2013

Cataract News and Research

Latest Cataract News and Research

Omeros seeks EMA's approval to market OMS302 for patients undergoing ILR surgery

Study: People with cataract-related vision loss who undergo cataract surgery live longer

Meta-analysis indicates protective effect of statins in preventing cataracts

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

Study reveals elegant circuit in visual system helps dictate how eyes connect to brain

STAAR Surgical receives regulatory approval for its Visian ICL with CentraFLOW technology in India

Oraya Therapy Stereotactic Radiotherapy for treatment of wet AMDs now available at Optegra

Omeros announces financial results for second quarter of 2013

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

NIH-funded study of aquaporin proteins could hold clues to cataract

Study opens door to possible treatments for variety of mitochondrial diseases

Researchers find a crucial on-off switch in visual development

Omeros submits OMS302 NDA to FDA for patients undergoing ILR surgery

Patient-reported outcomes may lead to new insights for improving cataract care

Tel Aviv researcher says lessons from Israel's health-care system could optimize eye health

Eleven Biotherapeutics reports positive results from EBI-005 Phase 1b/2a study in patients with DED

Advanced optical measures may help predict change in visual acuity, study says

STAAR Surgical to market Visian ICL with CentraFLOW technology in Korea, Argentina

pSivida reports that NICE issues draft guidance for use of ILUVIEN for pseudophakic patients with DME

NICE Appraisal Committee reconfirms clinical effectiveness of ILUVIEN

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Cataract News and Research

Latest Cataract News and Research

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in